Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Dr. Lal PathLabs Limited
  6. News
  7. Summary
    539524   INE600L01024

DR. LAL PATHLABS LIMITED

(539524)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Suburban Diagnostics Reportedly in Sale Talks with Dr. Lal PathLabs, Metropolis, Pharmeasy, Others

06/18/2021 EST

Suburban Diagnostics (India) Private Limited is in talks with Dr. Lal PathLabs Limited (BSE:539524), Metropolis Healthcare Limited (NSEI:METROPOLIS), PharmEasy, and a clutch of private equity funds for a complete sale, people close to the development said. The Mumbai-based diagnostics chain, backed by Sequoia Capital, has received bids ranging from INR 8,000 million to INR 12,000 million for the buyout, said two people in the know. "Both Dr. Lal Path Labs, Metropolis are interested and have offered INR 10,000 million - INR 12,000 million. They are also talking to online pharmacy player PharmEasy.," said one of the people on the condition of anonymity as the deal talks are private. Another person said that a few mid-sized PE funds have also been approached and bids have been submitted. Suburban Diagnostics has seen a manifold jump in business since the coronavirus outbreak last year. While other pathological tests saw a decline, Covid-related testing and home collection have registered a major spike, said another person with knowledge of the company's plans. Sanjay Arora, Suburban Diagnostics' managing director, did not immediately respond to queries from ET. Sequoia Capital had in 2012 invested INR 400 million in Suburban. It currently owns about 16% in the company and the remaining stake is with the promoter. Sequoia has been drawing up an exit plan from the company since 2018 and explored several options including an initial public offering (IPO), said people with knowledge of the development.


ę S&P Capital IQ 2021
All news about DR. LAL PATHLABS LIMITED
11/12Dr. Lal Pathlabs Completes Acquisition of Suburban Diagnostics (India)
MT
11/12Dr. Lal PathLabs Limited completed the acquisition of Suburban Diagnostics Private Limi..
CI
10/26Dr. Lal PathLabs' Consolidated Profit Climbs in Fiscal Q2 But Misses Estimates
MT
10/26Dr. Lal PathLabs to Acquire Indian Diagnostics Chain for Over $123 Million
MT
10/26Dr. Lal PathLabs Limited Reports Earnings Results for the Second Quarter and Six Months..
CI
10/26Dr. Lal PathLabs Limited entered into a definitive agreement to acquire Suburban Diagno..
CI
08/03DR LAL PATHLABS : Nomura Adjusts Dr. Lal Pathlabs' Price Target to 2,465 Indian Rupees Fro..
MT
08/02DR LAL PATHLABS : . Lal PhathLabs' Consolidated Profit Soars in Fiscal Q1
MT
07/30Dr. Lal Pathlabs Limited Declares Interim Dividend for the Financial Year 2021-2022, Pa..
CI
07/30Dr. Lal Pathlabs Limited Reports Earnings Results for the First Quarter Ended June 30, ..
CI
More news
Analyst Recommendations on DR. LAL PATHLABS LIMITED
More recommendations
Financials
Sales 2022 20 540 M 273 M 273 M
Net income 2022 3 983 M 53,0 M 53,0 M
Net cash 2022 11 208 M 149 M 149 M
P/E ratio 2022 77,5x
Yield 2022 0,48%
Capitalization 306 B 4 067 M 4 070 M
EV / Sales 2022 14,4x
EV / Sales 2023 12,8x
Nbr of Employees 3 996
Free-Float 37,9%
Chart DR. LAL PATHLABS LIMITED
Duration : Period :
Dr. Lal PathLabs Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DR. LAL PATHLABS LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Last Close Price 3 704,50 INR
Average target price 3 294,90 INR
Spread / Average Target -11,1%
EPS Revisions
Managers and Directors
Bharath Uppiliappan Chief Executive Officer
Ved Prakash Goel Chief Financial Officer
Arvind Lal Executive Chairman
Munender Soperna Chief Information Officer
Rajat Kalra Secretary, Compliance Officer & Head-Legal
Sector and Competitors